Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer.

Next Previous
X
Search
Trial Profile

A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Letrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ABCSG-34

    • Most Recent Events

    • 04 Jun 2024 Results assessing the efficacy and safety of tecemotide in patients with early BC when given concomitantly with neoadjuvant Standard-of-Care (SoC) treatment, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Dec 2021 Results published in the Clinical Cancer Research
    • 04 Jun 2020 EndoPredict test results published in the Myriad Genetics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top